Approaches to cholinergic therapy in Alzheimer's disease.
Iversen
L L
LL
Neuroscience Research Centre, Merck Sharp & Dohme Research Laboratories, Harlow, Essex, UK.
D000344:Afferent Pathways / Q000473:pathology; D000368:Aged; D000369:Aged, 80 and over; D000544:Alzheimer Disease / Q000188:drug therapy* / Q000453:epidemiology / Q000473:pathology; D000818:Animals; D002540:Cerebral Cortex / Q000473:pathology; D002799:Cholinergic Fibers / Q000473:pathology; D015195:Drug Design; D006168:Guinea Pigs; D006624:Hippocampus / Q000473:pathology; D006801:Humans; D051379:Mice; D009414:Nerve Growth Factors / Q000627:therapeutic use; D010277:Parasympathomimetics / Q000737:chemistry / Q000627:therapeutic use*; D015995:Prevalence; D051381:Rats; D011976:Receptors, Muscarinic / Q000187:drug effects / Q000502:physiology; D013329:Structure-Activity Relationship
D009414:Nerve Growth Factors; D010277:Parasympathomimetics; D011976:Receptors, Muscarinic